Arcellx Announces Pricing of Initial Public Offering
Congrats to BioHealth Capital Region-based Arcellx on their IPO! This Maryland biotech company is working to create exciting new cell therapies that have greater potency and improved target specificity to treat cancers such as multiple myeloma, acute myeloid leukemia, and solid tumors.
GAITHERSBURG, Md., Feb. 04, 2022 (GLOBE NEWSWIRE) – Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the pricing of its initial public offering of 8,250,000 shares of common stock at a public offering price of $15.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expeenses payable by Arcellx, are expected to be approximately $123.8 million.
Read the full article at: ir.arcellx.com
- About the Author
- Latest Posts
BioBuzz is a community led, experience focused, biotech and life sciences media and events company. BioBuzz highlights regional breaking news, industry professionals, jobs, events, and resources for business and career growth. Their weekly newsletter is subscribed to by thousands in the BioHealth Capital Region and Greater Philadelphia as the go-to for industry updates.